Peptides for therapy and diagnosis of alzheimer's disease

Current Pharmaceutical Design

Volumn 18, Issue 6, 2012, Pages 755-767

  Funke, Susanne Aileen ^a   Willbold, Dieter ^b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Amyloid ; Diagnosis; Peptides; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; PROLINE; PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; COMBINATORIAL LIBRARY; DISEASE COURSE; EVIDENCE BASED PRACTICE; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN PRECURSOR; DRUG DISCOVERY; HUMANS; PEPTIDE LIBRARY; PEPTIDES;

EID: 84856450292     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799277752     Document Type: Article

References (136)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers & Dementia. 2007; 3(3): 186-91.
2. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. All Z psychait. 1907; 64: 146-8.
3. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989; 3(4): 519-26.
4. Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, et al. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol. 2007; 171(3): 976-92.
5. Vieira MN, Forny-Germano L, Saraiva LM, Sebollela A, Martinez AM, Houzel JC, et al. Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration. J Neurochem. 2007; 103(2): 736-48.
6. Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis. 2007; 4(1): 13-27.
7. Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 1993; 75(6): 1039-42.
8. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987; 325(6106): 733-6.
9. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 1989; 57(1): 115-26.
10. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256(5054): 184-5.
11. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991; 6(4): 487-98.
12. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid betapeptide. Nat Rev Mol Cell Biol. 2007; 8(2): 101-12.
13. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDAtype glutamate receptor-dependent signaling pathway. J Neurosci. 2007; 27(11): 2866-75.
14. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008; 14(8): 837-42.
15. Ballatore C, Brunden KR, Trojanowski JQ, Lee VM, Smith AB, 3rd, Huryn D. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies. Curr Top Med Chem 2011; 11(3): 317-30.
16. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996; 93(20): 11213-8.
17. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem. 1999; 72(3): 1283-93.
18. Gozes I. Tau pathology and future therapeutics. Curr Alzheimer Res. 2010; 7(8): 685-96.
19. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008; 325(1): 146-53.
20. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis. 2009; 34(2): 381-8.
21. Stewart AJ, Fox A, Morimoto BH, Gozes I. Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs. 2007; 16(8): 1183-96.
22. Jakob-Roetne R, Jacobsen H. Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl. 2009; 48(17): 3030-59.
23. Nerelius C, Johansson J, Sandegren A. Amyloid beta-peptide aggregation. What does it result in and how can it be prevented? Front Biosci. 2009; 14: 1716-29.
24. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem. 2000 Jun 16; 275(24): 18495-502.
25. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006; 60(6): 668-76.
26. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007; 28(4): 537-47.
27. Price KA, Crouch PJ, White AR. Therapeutic treatment of Alzheimer's disease using metal complexing agents. Recent Pat CNS Drug Discov. 2007; 2(3): 180-7.
28. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, et al. EGCG remodels mature {alpha}-synuclein and amyloid-{beta} fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A. 2010.
29. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008; 15(6): 558-66.
30. Nagel-Steger L, Demeler B, Meyer-Zaika W, Hochdorffer K, Schrader T, Willbold D. Modulation of aggregate size- and shapedistributions of the amyloid-beta peptide by a designed beta-sheet breaker. Eur Biophys J. 2010; 39(3): 415-22.
31. Danho W, Swistok J, Khan W, Chu XJ, Cheung A, Fry D, et al. Opportunities and challenges of developing peptide drugs in the pharmaceutical industry. Adv Exp Med Biol. 2009; 611: 467-9.
32. Estrada LD, Soto C. Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem. 2007; 7(1): 115-26.
33. Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol. 2003; 21(12): 556-62.
34. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004; 45(4): 594-607.
35. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004; 12(6): 554-70.
36. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997; 18(4): 351-7.
37. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002; 58(12): 1791-800.
38. Nordberg A. Amyloid imaging in early detection of Alzheimer's disease. Neurodegener Dis. 2010; 7(1-3): 136-8.
39. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal Biochem. 1999; 266(1): 66-76.
40. Kang CK, Jayasinha V, Martin PT. Identification of peptides that specifically bind Abeta1-40 amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display. Neurobiol Dis. 2003; 14(1): 146-56.
41. Funke SA, Willbold D. Mirror image phage display--a method to generate D-peptide ligands for use in diagnostic or therapeutical applications. Mol Biosyst. 2009; 5(8): 783-6.
42. Schumacher TN, Mayr LM, Minor DL, Jr., Milhollen MA, Burgess MW, Kim PS. Identification of D-peptide ligands through mirrorimage phage display. Science. 1996; 271(5257): 1854-7.
43. Wiesehan K, Willbold D. Mirror-image phage display: aiming at the mirror. Chembiochem: a European journal of chemical biology. [Review]. 2003; 4(9): 811-5.
44. Gallop MA, Barrett RW, Dower WJ, Fodor SP, Gordon EM. Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J Med Chem. 1994; 37(9): 1233-51.
45. Bartnik D, Funke SA, Andrei-Selmer LC, Bacher M, Dodel R, Willbold D. Differently selected D-enantiomeric peptides act on different Abeta species. Rejuvenation research. 2010; 13(2-3): 202-5.
46. Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E, et al. Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display. Chembiochem. 2003; 4(8): 748-53.
47. van Groen T, Kadish I, Wiesehan K, Funke SA, Willbold D. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem. 2009; 4(2): 276-82.
48. Larbanoix L, Burtea C, Laurent S, Van Leuven F, Toubeau G, Vander Elst L, et al. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging. 2010; 31(10): 1679-89.
49. Larbanoix L, Burtea C, Ansciaux E, Laurent S, Mahieu I, Vander Elst L, et al. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library. Peptides. 2011; 32: 1232-43.
50. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996; 271(15): 8545-8.
51. Tjernberg LO, Lilliehook C, Callaway DJ, Naslund J, Hahne S, Thyberg J, et al. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem. 1997; 272(19): 12601-5.
52. Matsunaga Y, Fujii A, Awasthi A, Yokotani J, Takakura T, Yamada T. Eight-residue Abeta peptides inhibit the aggregation and enzymatic activity of Abeta42. Regul Pept. 2004; 120(1-3): 227-36.
53. Chafekar SM, Malda H, Merkx M, Meijer EW, Viertl D, Lashuel HA, et al. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation. Chembiochem. 2007; 8(15): 1857-64.
54. Zhang G, Leibowitz MJ, Sinko PJ, Stein S. Multiple-peptide conjugates for binding beta-amyloid plaques of Alzheimer's disease. Bioconjug Chem. 2003; 14(1): 86-92.
55. Austen BM, Paleologou KE, Ali SA, Qureshi MM, Allsop D, El- Agnaf OM. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. Biochemistry. 2008; 47(7): 1984-92.
56. Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, et al. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry. 2010; 49(15): 3261-72.
57. Matharu B, El-Agnaf O, Razvi A, Austen BM. Development of retro-inverso peptides as anti-aggregation drugs for beta-amyloid in Alzheimer's disease. Peptides. 2010; 31(10): 1866-72.
58. Bond JP, Deverin SP, Inouye H, el-Agnaf OM, Teeter MM, Kirschner DA. Assemblies of Alzheimer's peptides A beta 25-35 and A beta 31-35: reverse-turn conformation and side-chain interactions revealed by X-ray diffraction. J Struct Biol. 2003; 141(2): 156-70.
59. Liu R, McAllister C, Lyubchenko Y, Sierks MR. Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. J Neurosci Res. 2004; 75(2): 162-71.
60. Yan XZ, Qiao JT, Dou Y, Qiao ZD. Beta-amyloid peptide fragment 31-35 induces apoptosis in cultured cortical neurons. Neuroscience. 1999; 92(1): 177-84.
61. Fulop L, Zarandi M, Datki Z, Soos K, Penke B. Beta-amyloidderived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity. Biochem Biophys Res Commun. 2004; 324(1): 64-9.
62. Fradinger EA, Monien BH, Urbanc B, Lomakin A, Tan M, Li H, et al. C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity. Proc Natl Acad Sci U S A. 2008; 105(37): 14175-80.
63. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90(20): 9649-53.
64. Golabek AA, Soto C, Vogel T, Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J Biol Chem. 1996; 271(18): 10602-6.
65. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994; 145(5): 1030-5.
66. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, et al. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol. 2004; 165(3): 937-48.
67. Ma J, Brewer HB, Jr., Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A betarelated peptides. Neurobiol Aging. 1996; 17(5): 773-80.
68. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996; 226(3): 672-80.
69. Ghanta J, Shen CL, Kiessling LL, Murphy RM. A strategy for designing inhibitors of beta-amyloid toxicity. J Biol Chem. 1996; 271(47): 29525-8.
70. Gibson TJ, Murphy RM. Design of peptidyl compounds that affect beta-amyloid aggregation: importance of surface tension and context. Biochemistry. 2005; 44(24): 8898-907.
71. Kim JR, Gibson TJ, Murphy RM. Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides. J Biol Chem. 2003; 278(42): 40730-5.
72. Kim JR, Murphy RM. Mechanism of accelerated assembly of betaamyloid filaments into fibrils by KLVFFK(6). Biophys J. 2004; 86(5): 3194-203.
73. Lowe TL, Strzelec A, Kiessling LL, Murphy RM. Structurefunction relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry. 2001; 40(26): 7882-9.
74. Moss MA, Nichols MR, Reed DK, Hoh JH, Rosenberry TL. The peptide KLVFF-K(6) promotes beta-amyloid(1-40) protofibril growth by association but does not alter protofibril effects on cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT). Mol Pharmacol. 2003; 64(5): 1160-8.
75. Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM. Recognition sequence design for peptidyl modulators of betaamyloid aggregation and toxicity. Biochemistry. 1999; 38(12): 3570-8.
76. Sun X, Wu WH, Liu Q, Chen MS, Yu YP, Ma Y, et al. Hybrid peptides attenuate cytotoxicity of beta-amyloid by inhibiting its oligomerization: implication from solvent effects. Peptides. 2009; 30(7): 1282-7.
77. Gordon DJ, Meredith SC. Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. Biochemistry. 2003; 42(2): 475-85.
78. Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of betaamyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry. 2001; 40(28): 8237-45.
79. Etienne MA, Aucoin JP, Fu Y, McCarley RL, Hammer RP. Stoichiometric inhibition of amyloid beta-protein aggregation with peptides containing alternating alpha,alpha-disubstituted amino acids. J Am Chem Soc. 2006; 128(11): 3522-3.
80. Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, et al. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry. 2006; 45(17): 5503-16.
81. Rangachari V, Davey ZS, Healy B, Moore BD, Sonoda LK, Cusack B, et al. Rationally designed dehydroalanine (DeltaAla)-containing peptides inhibit amyloid-beta (Abeta) peptide aggregation. Biopolymers. 2009; 91(6): 456-65.
82. Wood SJ, Wetzel R, Martin JD, Hurle MR. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry. 1995; 34(3): 724-30.
83. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998; 4(7): 822-6.
84. Sigurdsson EM, Permanne B, Soto C, Wisniewski T, Frangione B. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 2000; 59(1): 11-7.
85. Chacon MA, Barria MI, Soto C, Inestrosa NC. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry. 2004; 9(10): 953-61.
86. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 2002; 16(8): 860-2.
87. Datki Z, Papp R, Zadori D, Soos K, Fulop L, Juhasz A, et al. In vitro model of neurotoxicity of Abeta 1-42 and neuroprotection by a pentapeptide: irreversible events during the first hour. Neurobiol Dis. 2004; 17(3): 507-15.
88. Juhasz G, Marki A, Vass G, Fulop L, Budai D, Penke B, et al. An intraperitoneally administered pentapeptide protects against Abeta (1-42) induced neuronal excitation in vivo. J Alzheimers Dis. 2009; 16(1): 189-96.
89. Szegedi V, Fulop L, Farkas T, Rozsa E, Robotka H, Kis Z, et al. Pentapeptides derived from Abeta 1-42 protect neurons from the modulatory effect of Abeta fibrils--an in vitro and in vivo electrophysiological study. Neurobiol Dis. 2005; 18(3): 499-508.
90. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem. 1995; 64(1): 253-65.
91. Shearman MS, Ragan CI, Iversen LL. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of betaamyloid-mediated cell death. Proc Natl Acad Sci U S A. 1994; 91(4): 1470-4.
92. Terzi E, Holzemann G, Seelig J. Reversible random coil-beta-sheet transition of the Alzheimer beta-amyloid fragment (25-35). Biochemistry. 1994; 33(6): 1345-50.
93. Doig AJ, Hughes E, Burke RM, Su TJ, Heenan RK, Lu J. Inhibition of toxicity and protofibril formation in the amyloid-beta peptide beta(25-35) using N-methylated derivatives. Biochem Soc Trans. 2002; 30(4): 537-42.
94. Hughes E, Burke RM, Doig AJ. Inhibition of toxicity in the betaamyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J Biol Chem. 2000; 275(33): 25109-15.
95. Gordon DJ, Tappe R, Meredith SC. Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis. J Pept Res. 2002; 60(1): 37-55.
96. Cruz M, Tusell JM, Grillo-Bosch D, Albericio F, Serratosa J, Rabanal F, et al. Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids. J Pept Res. 2004; 63(3): 324-8.
97. Grillo-Bosch D, Carulla N, Cruz M, Sanchez L, Pujol-Pina R, Madurga S, et al. Retro-enantio N-methylated peptides as betaamyloid aggregation inhibitors. ChemMedChem. 2009; 4(9): 1488-94.
98. Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem. 2002; 2(4): 417-23.
99. Jhee. Single dose escalation study of PPI-1019, an A-beta aggregation Inhibitor. New Clinical drug evaluation unit, Boca Raaton, FL. 2003.
100. Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 2006; 45(32): 9906-18.
101. Findeis MA, Lee JJ, Kelley M, Wakefield JD, Zhang MH, Chin J, et al. Characterization of cholyl-leu-val-phe-phe-ala-OH as an inhibitor of amyloid beta-peptide polymerization. Amyloid. 2001; 8(4): 231-41.
102. Findeis MA, Musso GM, Arico-Muendel CC, Benjamin HW, Hundal AM, Lee JJ, et al. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry. 1999; 38(21): 6791-800.
103. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, Gazit E. Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed Engl. 2009; 48(11): 1981-6.
104. Gilead S, Gazit E. Inhibition of amyloid fibril formation by peptide analogues modified with alpha-aminoisobutyric acid. Angew Chem Int Ed Engl. 2004; 43(31): 4041-4.
105. Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993; 217: 228-57.
106. Blanchard BJ, Hiniker AE, Lu CC, Margolin Y, Yu AS, Ingram VM. Elimination of Amyloid beta Neurotoxicity. J Alzheimers Dis. 2000; 2(2): 137-49.
107. Blanchard BJ, Konopka G, Russell M, Ingram VM. Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease. Brain Res. 1997; 776(1-2): 40-50.
108. Schwarzman AL, Tsiper M, Gregori L, Goldgaber D, Frakowiak J, Mazur-Kolecka B, et al. Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation. Amyloid. 2005; 12(4): 199-209.
109. Orner BP, Liu L, Murphy RM, Kiessling LL. Phage display affords peptides that modulate beta-amyloid aggregation. J Am Chem Soc. 2006; 128(36): 11882-9.
110. Taddei K, Laws SM, Verdile G, Munns S, D'Costa K, Harvey AR, et al. Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity. Neurobiol Aging. 2008; 31(2): 203-14.
111. Baine M, Georgie DS, Shiferraw EZ, Nguyen TP, Nogaj LA, Moffet DA. Inhibition of Abeta42 aggregation using peptides selected from combinatorial libraries. J Pept Sci. 2009; 15(8): 499-503.
112. Funke SA, van Groen T, Kadish I, Bartnik D, Nagel-Steger L, Brener O, et al. Oral Treatment with the D-Enantiomeric Peptide D3 Improves the Pathology and Behavior of Alzheimer's Disease Transgenic Mice. Acs Chem Neurosci. 2010; 1(9): 639-48.
113. van Groen T, Wiesehan K, Funke SA, Kadish I, Nagel-Steger L, Willbold D. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. ChemMedChem. 2008; 3(12): 1848-52.
114. Liu H, Funke SA, Willbold D. Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model. Rejuvenation Research 2010; 13(2-3): 210-3.
115. Muller-Schiffmann A, Marz-Berberich J, Andreyeva A, Ronicke R, Bartnik D, Brener O, et al. Combining independent drug classes into superior, synergistically acting hybrid molecules. Angew Chem Int Ed Engl. 2010; 49(46): 8743-6.
116. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res. 1968; 9(2): 155-67.
117. Fielding PE, Nagao K, Hakamata H, Chimini G, Fielding CJ. A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-1. Biochemistry 2000; 39(46): 14113-20.
118. Navab M, Anantharamaiah GM, Fogelman AM. The role of highdensity lipoprotein in inflammation. Trends Cardiovasc Med. 2005; 15(4): 158-61.
119. Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, Magdesian MH, et al. Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol. 2009; 41(6): 1361-70.
120. Handattu SP, Garber DW, Monroe CE, van Groen T, Kadish I, Nayyar G, et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol Dis. 2009; 34(3): 525-34.
121. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res. 1992; 33(2): 141-66.
122. Anantharamaiah GM, Mishra VK, Garber DW, Datta G, Handattu SP, Palgunachari MN, et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein AI mimetic peptides. J Lipid Res. 2007; 48(9): 1915-23.
123. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med. 2006; 3(10): 540-7.
124. Shah PK, Chyu KY. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med. [Review]. 2005; 15(8): 291-6.
125. Li L, Cao D, Garber DW, Kim H, Fukuchi K. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. The American journal of pathology. 2003; 163(6): 2155-64.
126. Kunjathoor VV, Tseng AA, Medeiros LA, Khan T, Moore KJ. beta- Amyloid promotes accumulation of lipid peroxides by inhibiting CD36-mediated clearance of oxidized lipoproteins. J Neuroinflammation. 2004; 1(1): 23.
127. Cao D, Fukuchi K, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiology of aging. 2006; 27(11): 1632-43.
128. Kawasaki T, Onodera K, Kamijo S. Selection of peptide inhibitors of soluble Abeta(1-42) oligomer formation by phage display. Bioscience, biotechnology, and biochemistry. 2010; 74(11): 2214-9.
129. Fauchere JL, Thurieau, C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Advances in Drug Research. 1992; 23: 127-59.
130. Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2002; 9(9): 963-78.
131. Adessi C, Frossard MJ, Boissard C, Fraga S, Bieler S, Ruckle T, et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem. 2003; 278(16): 13905-11.
132. Hetenyi C, Szabo Z, Klement E, Datki Z, Kortvelyesi T, Zarandi M, et al. Pentapeptide amides interfere with the aggregation of beta amyloid peptide of Alzheimer's disease. Biochem Biophys Res Commun. 2002; 292(4): 931-6.
133. Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, et al. Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J Biol Chem. 2003; 278(37): 34874-81.
134. Pappenheimer JR, Karnovsky ML, Maggio JE. Absorption and excretion of undegradable peptides: role of lipid solubility and net charge. J Pharmacol Exp Ther. 1997; 280(1): 292-300.
135. Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol. 1999; 39(3): 371-82.
136. Rocha S, Cardoso I, Borner H, Pereira MC, Saraiva MJ, Coelho M. Design and biological activity of beta-sheet breaker peptide conjugates. Biochem Biophys Res Commun. 2009; 380(2): 397-401.